Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) generates news across animal health, regenerative medicine and veterinary-focused artificial intelligence. The company, together with its subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., reports on developments in its veterinary medical devices, platelet-rich plasma products and AI platforms designed for companion animals and horses.
News coverage for PetVivo often highlights updates on its lead products SPRYNG® with OsteoCushion® technology and PrecisePRP®, including distribution agreements, clinical adoption by veterinary practices and educational initiatives such as continuing education courses and conference presentations. Press releases also describe how these products are promoted through vendor partnerships and distributor networks, as well as their use in managing osteoarthritis, lameness and other joint-related conditions in cats, dogs and horses.
Another key theme in PetVivo news is its expansion into veterinary AI and digital platforms. Announcements have detailed the launch of the PetVivo.ai platform, an AI-powered system intended to improve veterinary client acquisition and engagement through multiple specialized AI agents. Additional releases cover PetVivo’s exclusive 10-year white-label licensing agreement for the Agentic Pet AI framework, publication of a technical whitepaper validating this multi-agent architecture and plans for dual-platform launches that connect pet parents with veterinary practices.
Investors and veterinary professionals following PETV news can also see updates on strategic alliances, board appointments, investor conference presentations and financial results. Earnings-related releases describe revenue trends, product mix developments and distribution expansion, while corporate announcements provide insight into capital structure actions and governance changes. For ongoing context around PetVivo’s products, partnerships and AI initiatives, this news feed offers a centralized view of the company’s public disclosures.
PetVivo Holdings (OTCQB: PETV) reported preliminary unaudited financial results for fiscal year 2025, marking significant growth and operational achievements. The company's revenue increased 17% to $1.1 million, driven by the expansion of Spryng® with OsteoCushion™ Technology from equine to companion animal markets.
Key financial metrics include a 31% increase in distributor network sales to $958,000, representing 85% of total revenues. The company's gross profit rose 15% to $995,000 with an 87.8% margin. Operating loss decreased 24% to $8.1 million, while net loss improved 27% to $8 million. Cash position strengthened to $3.3 million as of June 30, 2025, following a $4.4 million equity financing.
Operational highlights include reaching over 1,000 veterinary clinics across all 50 states, strategic partnerships with Digital Landia for AI integration, and VetStem for PrecisePRP® commercialization. The company strengthened its leadership team with key appointments and expanded its distribution network by adding Vedco and Clipper Distributing, while also entering the international market through a Mexican distribution agreement.
PetVivo Holdings (OTCQB: PETV), a biomedical company focused on therapeutic medical devices for animals, has scheduled its fiscal fourth quarter and full year 2025 earnings conference call for Monday, June 30, 2025, at 5:00 p.m. ET.
The company will release its financial results for the period ended March 31, 2025, before the conference call. Management will host a presentation followed by a Q&A session. Investors can access the call through a toll-free dial-in number or webcast, with a replay available afterward through the company's investor relations website.
PetVivo Holdings (OTCQB: PETV) has successfully completed its $5 million Series B Convertible Preferred Stock offering with the final $1 million purchase option exercise. The Series B shares are priced at $1.00 per share with a 1:1 conversion ratio to common stock.
The funding will support the commercialization of two key products: SPRYNG®, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. PrecisePRP® offers consistent dosing with 4 billion platelets per vial and eliminates the need for blood draws or centrifugation.
Digital Landia and PetVivo Holdings (OTCQB: PETV) have announced the launch of an invite-only MVP (minimum viable product) of Agentic.Pet, an autonomous pet artificial intelligence ecosystem. The platform, officially launched on May 23, 2025, is entering a stress-testing and debugging phase with select early adopters.
The MVP includes AI agents for veterinary diagnostics, behavioral analysis, and nutritional advising. Upcoming enhancements will feature pet facial recognition and specialized AI agents for blood tests, urine analysis, and radiological imaging. Access is currently limited to pet industry professionals and tech enthusiasts through an invite code system available at www.agenticpet.io.
PetVivo Holdings (OTCQB: PETV) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference, scheduled for May 14, 2025, at The Plaza Hotel in New York City. The company's CEO, John Lai, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. ET. Investors and stakeholders interested in scheduling meetings can contact John Perez at D. Boral Capital.
PetVivo Holdings (OTCQB: PETV) has signed a distribution agreement with Eq Especialidades to market and distribute Spryng™ with OsteoCushion™ technology throughout Mexico, effective April 1, 2025.
Spryng™ is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles. The technology works by adsorbing onto animal joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It aids in managing noninfectious joint pain conditions including joint instability, degenerative joint disease, and osteoarthritis.
This strategic partnership aims to expand PetVivo's presence in the Mexican animal health market, targeting both equine and companion animal segments.